BioCorRx Provides Business Update for the Third Quarter of 2018

ANAHEIM, CA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx, Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the third quarter ended September 30, 2018.

Brady Granier, CEO, President, and Director of BioCorRx, Inc., stated, “We continue to work on the advancement of BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. In early October, we received a Just-In-Time (JIT) request from NIDA on our grant application submitted in May of this year. We submitted the requested information last month and the grant application is now pending administrative review as of today. Although we were not given the exact administrative review date in our most recent update from NIDA, we expect to know the results of that review soon after it is completed. While we continue to feel positive about the grant opportunity, our work is progressing on the advancement of BICX102 regardless of the grant outcome. We are extremely encouraged by the outlook for the business.”

Lourdes Felix, CFO, COO, and Director of BioCorRx, commented, “We continue to work diligently towards advancing BICX102, including build out of the machinery and procurement of ingredients. We have also added additional industry experts to help in planning so that we are fully prepared when we initiate the next phase of our drug development program. We also continue to participate in industry conferences. In September, we hosted an exhibit at the 2nd Annual National Opioid Crisis Management Congress in Washington, DC. We met with top thought leaders and received positive feedback on our BioCorRx® Recovery Program.”

About BioCorRx

BioCorRx, Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.


Contact Data